Mu-Jie Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mu-Jie Lu has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Xiaolu Ang Cambronne
Department of Molecular Biosciences, The University of Texas at Austin, Austin, USA
6 shared publications - Stefano Tiziani
Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX
3 shared publications Crystal N. Wilson
Department of Molecular Biosciences, The University of Texas at Austin, Austin, USA
2 shared publicationsHsin-Ru Chan
Department of Molecular Biosciences, The University of Texas at Austin, Austin, USA
2 shared publications- Jonathan Busquets
University of Texas at Austin, Austin, TX
2 shared publications - Valeria Impedovo
Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX
2 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Springer Nature in Nature Chemical Biology
- Vol. 22 (11) , 1843-1853
A covalent PFKL activator suppresses tumor growth
- 5 August 2026
- Published by Springer Nature in Nature Chemical Biology
- Vol. 22 (11) , 1843-1853
Open AccessA covalent PFKL activator suppresses tumor growth
- 13 February 2024
- Published by Elsevier in Cell Metabolism
- Vol. 36 (4) , 808-821.e6
SLC25A51 decouples the mitochondrial NAD+/NADH ratio to control proliferation of AML cells
- 13 February 2024
- Published by Elsevier in Cell Metabolism
- Vol. 36 (4) , 808-821.e6
SLC25A51 decouples the mitochondrial NAD+/NADH ratio to control proliferation of AML cells
- 14 August 2023
- Published by Springer Nature in EMBO Reports
- Vol. 24 (10) , e56596
Dynamics of SLC25A51 reveal preference for oxidized NAD+ and substrate led transport
SLC25A51 is a member of the mitochondrial carrier family (MCF) but lacks key residues that contribute to the mechanism of other nucleotide MCF transporters. Thus, how SLC25A51 transports NAD+ across the inner mitochondrial membrane remains unclear. To elucidate its mechanism, we use Molecular Dynamics simulations to reconstitute SLC25A51 homology models into lipid bilayers and to generate hypotheses to test. We observe spontaneous binding of cardiolipin phospholipids to three distinct sites on the exterior of SLC25A51's central pore and find that mutation of these sites impairs cardiolipin binding and transporter activity. We also observe that stable formation of the required matrix gate is controlled by a single salt bridge. We identify binding sites in SLC25A51 for NAD+ and show that its selectivity for NAD+ is guided by an electrostatic interaction between the charged nicotinamide ring in the ligand and a negatively charged patch in the pore. In turn, interaction of NAD+ with interior residue E132 guides the ligand to dynamically engage and weaken the salt bridge gate, representing a ligand-induced initiation of transport.
- 14 August 2023
- Published by Springer Nature in EMBO Reports
- Vol. 24 (10) , e56596
Dynamics of SLC25A51 reveal preference for oxidized NAD+ and substrate led transport
SLC25A51 is a member of the mitochondrial carrier family (MCF) but lacks key residues that contribute to the mechanism of other nucleotide MCF transporters. Thus, how SLC25A51 transports NAD+ across the inner mitochondrial membrane remains unclear. To elucidate its mechanism, we use Molecular Dynamics simulations to reconstitute SLC25A51 homology models into lipid bilayers and to generate hypotheses to test. We observe spontaneous binding of cardiolipin phospholipids to three distinct sites on the exterior of SLC25A51's central pore and find that mutation of these sites impairs cardiolipin binding and transporter activity. We also observe that stable formation of the required matrix gate is controlled by a single salt bridge. We identify binding sites in SLC25A51 for NAD+ and show that its selectivity for NAD+ is guided by an electrostatic interaction between the charged nicotinamide ring in the ligand and a negatively charged patch in the pore. In turn, interaction of NAD+ with interior residue E132 guides the ligand to dynamically engage and weaken the salt bridge gate, representing a ligand-induced initiation of transport.
- Open Access
- 1 May 2023
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 4 (3_Suppleme) , A42
Abstract A42: SLC25A51 impacts drug sensitivity in AML cells by sustaining mitochondrial oxidative flux
SLC25A51 imports oxidized NAD+ into the mitochondrial matrix and is required for sustaining oxidative metabolism in human mitochondria. We observed that higher expression of SLC25A51 correlated with poorer survival in Acute Myeloid Leukemia (AML) patient data. Given AML’s dependency on oxidative cell metabolism, we sought to determine the role SLC25A51 may serve in this disease. We found that depleting SLC25A51 in AML cells led to increased apoptosis, as well as prolonged survival in a xenograft model. Metabolic flux analyses indicated that depletion of SLC25A51 shunted flux away from oxidative pathways and promoted glutamine utilization for reductive carboxylation to support aspartate production. Consequently, SLC25A51 loss sensitized AML cells to glutamine deprivation and glutaminase inhibitor CB-839. Together, the work highlights connections between SLC25A51 and oxidative mitochondrial flux in AML. We identified a rationale for targeting SLC25A51 in myeloid cancers with potential for a therapeutic window, especially when coupled with glutaminase inhibition. Citation Format: Mu-Jie Lu, Jonathan Busquets, Valeria Impedovo, Yu-Tai Chang, William Matsui, Stefano Tiziani, Xiaolu Cambronne. SLC25A51 impacts drug sensitivity in AML cells by sustaining mitochondrial oxidative flux [abstract]. In: Proceedings of the AACR Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome; 2023 Jan 23-25; Austin, TX. Philadelphia (PA): AACR; Blood Cancer Discov 2023;4(3_Suppl):Abstract nr A42.
- 1 May 2023
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 4 (3_Suppleme) , A42
Open AccessAbstract A42: SLC25A51 impacts drug sensitivity in AML cells by sustaining mitochondrial oxidative flux
SLC25A51 imports oxidized NAD+ into the mitochondrial matrix and is required for sustaining oxidative metabolism in human mitochondria. We observed that higher expression of SLC25A51 correlated with poorer survival in Acute Myeloid Leukemia (AML) patient data. Given AML’s dependency on oxidative cell metabolism, we sought to determine the role SLC25A51 may serve in this disease. We found that depleting SLC25A51 in AML cells led to increased apoptosis, as well as prolonged survival in a xenograft model. Metabolic flux analyses indicated that depletion of SLC25A51 shunted flux away from oxidative pathways and promoted glutamine utilization for reductive carboxylation to support aspartate production. Consequently, SLC25A51 loss sensitized AML cells to glutamine deprivation and glutaminase inhibitor CB-839. Together, the work highlights connections between SLC25A51 and oxidative mitochondrial flux in AML. We identified a rationale for targeting SLC25A51 in myeloid cancers with potential for a therapeutic window, especially when coupled with glutaminase inhibition. Citation Format: Mu-Jie Lu, Jonathan Busquets, Valeria Impedovo, Yu-Tai Chang, William Matsui, Stefano Tiziani, Xiaolu Cambronne. SLC25A51 impacts drug sensitivity in AML cells by sustaining mitochondrial oxidative flux [abstract]. In: Proceedings of the AACR Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome; 2023 Jan 23-25; Austin, TX. Philadelphia (PA): AACR; Blood Cancer Discov 2023;4(3_Suppl):Abstract nr A42.
- Open Access
SLC25A51 impacts drug sensitivity in AML cells by sustaining mitochondrial oxidative flux
SLC25A51 imports oxidized NAD + into the mitochondrial matrix and is required for sustaining oxidative metabolism in human mitochondria. We observed that higher expression of SLC25A51 correlated with poorer survival in Acute Myeloid Leukemia (AML) patient data. Given AML’s dependency on oxidative cell metabolism, we sought to determine the role SLC25A51 may serve in this disease. We found that depleting SLC25A51 in AML cells led to increased apoptosis, as well as prolonged survival in a xenograft model. Metabolic flux analyses indicated that depletion of SLC25A51 shunted flux away from oxidative pathways and promoted glutamine utilization for reductive carboxylation to support aspartate production. Consequently, SLC25A51 loss sensitized AML cells to glutamine deprivation and glutaminase inhibitor CB-839. Together, the work highlights connections between SLC25A51 and oxidative mitochondrial flux in AML. We identified a rationale for targeting SLC25A51 in myeloid cancers with potential for a therapeutic window, especially when coupled with glutaminase inhibition. Statement of significance: This investigation describes an approach to directly modulate the tricarboxylic acid cycle as a potential vulnerability in oxidative tumors. Using AML models, the work is an inaugural look into SLC25A51’s role supporting oxidative mitochondrial metabolism and identifies SLC25A51 levels as a potential marker for stratification of AML.
Open AccessSLC25A51 impacts drug sensitivity in AML cells by sustaining mitochondrial oxidative flux
SLC25A51 imports oxidized NAD + into the mitochondrial matrix and is required for sustaining oxidative metabolism in human mitochondria. We observed that higher expression of SLC25A51 correlated with poorer survival in Acute Myeloid Leukemia (AML) patient data. Given AML’s dependency on oxidative cell metabolism, we sought to determine the role SLC25A51 may serve in this disease. We found that depleting SLC25A51 in AML cells led to increased apoptosis, as well as prolonged survival in a xenograft model. Metabolic flux analyses indicated that depletion of SLC25A51 shunted flux away from oxidative pathways and promoted glutamine utilization for reductive carboxylation to support aspartate production. Consequently, SLC25A51 loss sensitized AML cells to glutamine deprivation and glutaminase inhibitor CB-839. Together, the work highlights connections between SLC25A51 and oxidative mitochondrial flux in AML. We identified a rationale for targeting SLC25A51 in myeloid cancers with potential for a therapeutic window, especially when coupled with glutaminase inhibition. Statement of significance: This investigation describes an approach to directly modulate the tricarboxylic acid cycle as a potential vulnerability in oxidative tumors. Using AML models, the work is an inaugural look into SLC25A51’s role supporting oxidative mitochondrial metabolism and identifies SLC25A51 levels as a potential marker for stratification of AML.
- Open Access
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
SLC25A51 is a Mitochondrial NAD Transporter
Tissue nicotinamide adenine dinucleotide (NAD) levels correlate with healthspan in laboratory rodents, falling with age or disease, and rising with exercise or caloric restriction. Moreover, the demonstration that supplemental NAD precursors confer beneficial effects in a variety of rodent models has led to a resurgence in interest in the basic biology of this molecule. Although it is widely recognized that NAD is present in the mitochondrial matrix and critical to the function of the organelle, the source of mitochondrial NAD has been debated. We recently used an isotopic labeling approach to demonstrate that direct uptake of intact NAD is one mechanism by which mitochondria are able to obtain this dinucleotide. Here, we identify SLC25A51 as a carrier that can mediate the transport of NAD across mitochondrial membranes. Compartment‐specific regulation of NAD concentration is an understudied process that likely plays crucial roles in the adaptation of cells and tissues to a changing metabolic environment. This work may ultimately reveal new therapeutic avenues to improve mitochondrial function.
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Open AccessSLC25A51 is a Mitochondrial NAD Transporter
Tissue nicotinamide adenine dinucleotide (NAD) levels correlate with healthspan in laboratory rodents, falling with age or disease, and rising with exercise or caloric restriction. Moreover, the demonstration that supplemental NAD precursors confer beneficial effects in a variety of rodent models has led to a resurgence in interest in the basic biology of this molecule. Although it is widely recognized that NAD is present in the mitochondrial matrix and critical to the function of the organelle, the source of mitochondrial NAD has been debated. We recently used an isotopic labeling approach to demonstrate that direct uptake of intact NAD is one mechanism by which mitochondria are able to obtain this dinucleotide. Here, we identify SLC25A51 as a carrier that can mediate the transport of NAD across mitochondrial membranes. Compartment‐specific regulation of NAD concentration is an understudied process that likely plays crucial roles in the adaptation of cells and tissues to a changing metabolic environment. This work may ultimately reveal new therapeutic avenues to improve mitochondrial function.